Author
Swathi Sugumar
Sr. Product Manager
Every electronic product information (ePI) programme looks credible from the outside. A team. A timeline. A platform conversation. What varies — and what determines whether the programme holds when deadline pressure arrives — is what was done before any of that. Five things. Most organizations, when they look honestly, have two or three.
With the European Medicines Agency’s ePI initiative moving from pilot towards network-wide rollout, EMA ePI compliance is shifting from a future consideration to a programme requirement. Electronic product information readiness is no longer about whether to start. It is about whether what you have started will hold.
The five dimensions of ePI readiness below are not a framework. They are the specific foundational work that separates organizations building credible ePI programmes from those that will be rebuilding theirs under deadline pressure. The gaps rarely appear alone. They tend to cluster — and understanding why they cluster is as important as knowing what they are. They are also the five areas a structured ePI readiness assessment examines first.
How Ready Is Your Organization for ePI?
Before the ePI readiness checklist — find yourself in one of these three stages.
| The difference between 02 and 03 is not sophistication. It is a sequence. |
The Organizations that struggle with ePI are not the ones that ignored it. They are the ones that acknowledged it, started a programme, and skipped the foundational work because it felt slow. The foundational work does not feel urgent when a deadline is eighteen months away. It feels urgent when the deadline is six months away and the programme is only now discovering what the estate actually contains. An honest ePI readiness assessment is the step that surfaces those discoveries while there is still time to act on them.
The Sequencing Problem in ePI Implementation
The five dimensions below are not a linear checklist. They are parallel workstreams. The label estate inventory informs the deadline mapping. The deadline mapping informs your ePI roadmap and the conversion complexity assessment. The conversion complexity assessment informs the build-buy-partner decision. The downstream mapping runs alongside all of them — because it affects every decision the programme makes.
Organizations in Stage 02 — moving but ungrounded — almost always have the same sequencing error. A platform decision made before the estate was understood. Conversion complexity scoped from a product count before a pilot revealed what the difficult labels required. The programme is moving. But it is moving on assumptions rather than evidence — and assumptions surface as problems at the worst possible moment.
The five dimensions are not five tasks to complete in order. There are five questions to answer in parallel before the programme commits to anything it cannot easily reverse.
The Five Dimensions of ePI Readiness
1. ePI Label Estate Inventory — not approximately, precisely
A structured inventory of every ePI-eligible label — by market, language variant, format, and lifecycle stage. This gap exists because no single team owns the full picture — regulatory knows the approved products, IT knows the systems, pharmaceutical labelling operations knows the formats, and the acquisition history lives in nobody’s current view. Every later ePI migration decision depends on knowing exactly what you are converting.
What we typically see: A rough product count. Real uncertainty around acquired labels, co-marketed products, and anything that came through M&A. Nobody is confident about the older formats.
2. ePI Regulatory Deadline Mapping — by product, not just by mandate
Specific products mapped to specific ePI regulatory requirements and timelines — not just the headline EMA ePI mandate date, but by product type, therapeutic area, and market. This gap exists because teams conflate the mandate date with their portfolio date — and the two are rarely the same once specific products are mapped against sequenced regulatory rollouts, such as those set out in the EMA ePI roadmap. Done properly, this mapping becomes your ePI roadmap.
What we typically see: The mandate is known. The products it applies to first are not mapped. Regulatory is waiting for IT. IT is waiting for regulatory. Nobody has sat in a room and done the mapping.
3. ePI Downstream Systems Mapping — every system that consumes your label today
Every platform, partner, and system that currently receives label content is identified and its role in the ePI implementation is understood. This gap exists because the label was never thought of as a data feed — it was a document that went to print and to a PDF, and what happened after that was someone else’s problem.
What we typically see: Genuine surprise when the downstream inventory reveals how many systems touch the label. Formulary platforms, medical information systems, patient portals, distributor feeds — each one a dependency the programme did not plan for.
4. ePI Conversion Complexity Assessment — on your labels, not industry averages
ePI label conversion effort estimated from a pilot on representative labels — including the difficult ones. Legacy formats, complex dosing structures, paediatric labels, multilingual variants. This gap exists because pilots feel slow when deadline pressure is building — so organizations skip them and rely on estimates that do not reflect what their specific label types actually require. Successful FHIR ePI conversion depends on how cleanly each label’s structure maps to the EU ePI FHIR Implementation Guide — and that only becomes visible on real labels.
What we typically see: Effort calculated by multiplying product count by an industry average. The straightforward labels have been considered. The difficult ones — the ones that will determine whether the programme holds — have not been opened.
5. ePI Build vs Buy vs Partner Strategy — held, not deferred
A formal evaluation of whether to build, buy, or partner for your pharmaceutical ePI implementation — based on GxP validation requirements, FHIR IG alignment complexity, and what internal IT actually covers. This gap exists because the decision feels reversible until it is not — and by the time the irreversibility becomes clear, the programme has already committed resources and time to a path that does not fit.
What we typically see: Decision deferred because it feels premature. Or made by default — internal IT assumed capable without a validation architecture in place, or a platform selected on a demo rather than a pilot on the organization’s own labels.
Most organizations that read this will recognise themselves somewhere across the three stages and five dimensions above. That recognition is the starting point. What matters is whether it becomes a conversation that changes something — or an observation that gets noted and set aside until the deadline removes the option to act on it properly.
“The deadline is fixed.
The amount of programme runway left is not.”
Is Your Organization ePI-Ready?
Assess your ePI readiness before regulatory deadlines force rushed decisions. Deevita’s ePI Readiness Assessment evaluates your label estate, conversion complexity, downstream architecture and programme readiness — giving your team a clear roadmap for implementation. Explore our wider electronic product information services and pharma and life sciences solutions.
